Landscapes / Targets

LAG-3

14 drugs act on LAG-3, in 36 active trials · Any stage · updated 18 Nov 2026

FollowEvery change as it happens, and a Monday email

Drugs14

DrugHow it worksCompanyStageNext dateDetails
BMS-986213not checked
—
Bristol Myers Squibb · Public BMY
On the market 26 May 2029Phase 4 trial completes
Monoclonal antibody
Bristol Myers Squibb · Public BMY
Approved 25 Aug 2029Phase 2 trial completes
LAG-3 antibody
Regeneron · Public REGN
Phase 3 15 Jan 2027Phase 3 trial completes
Soluble LAG-3 protein (immune activator)
Phase 3 Jun 2027Phase 3 trial completes
Monoclonal antibody
Merck & Co. · Public MRK
Phase 3 4 Aug 2043Phase 3 trial completes
—
Akeso · Public 9926.HK
Phase 1/2 Dec 2026Phase 1/2 trial completes
—
Phase 1/2 Dec 2026Phase 1/2 trial completes
Multi-specific immunoglobulin
Roche · Public ROG.SW
Phase 2 31 Dec 2026Phase 2 trial completes
Artificial immunoglobulin
Phase 1/2 —
—
Henlius · Public 2696.HK
Phase 2 —
—
Phase 1 Nov 2026soonPhase 1 trial completes
—
Phase 1 1 Mar 2027Phase 1 trial completes
—
Akeso · Public 9926.HK
Phase 1 May 2027Phase 1 trial completes
—
3SBio · Public 1530.HK
Phase 1 30 Sep 2027Phase 1 trial completes

About this list

Checked
13 of 14 drugs. The other 1 is marked “not checked” in the list. How we check
Matches
The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
Sources
ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LAG-3

Following is part of Solo: you see every change to LAG-3 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in